The choice of iron preparation in children with iron-deficiency anemia related to chronic kidney disease (CKD) includes tolerance and response.

The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...

NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

An abbreviated investigation flow chart is shown in figure ... prevalence of GI cancer was found in patients taking aspirin or warfarin, either alone or in combination, compared with patients not ...

U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive ...

A team of researchers has uncovered a previously unrecognized role of mitochondrial protein synthesis in the maintenance of intracellular iron distribution. Disruption of this process was found to ...

Patient centricity at its core is about keeping the patient’s circumstances, behaviours, and medication barriers in mind. Engaging patients and caregivers in healthcare decisions can positively ...

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

One of the major health troubles is anemia. Being anemic creates further health issues if not handled in the initial stages.

A major new study shows that giving heart attack patients a cholesterol-lowering combo treatment early on – not months later – can dramatically improve their outlook and even save lives. Patients trea ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.